目的为药品上市许可制度下委托生产双方的责任约定提供建议。方法通过查阅国内外法规及文献,分析上市许可制度下,美欧对药品委托生产的要求及委托双方责任约定的要素。结果美国食品药品管理局(U.S.Food and Drug Administration,FDA)建...目的为药品上市许可制度下委托生产双方的责任约定提供建议。方法通过查阅国内外法规及文献,分析上市许可制度下,美欧对药品委托生产的要求及委托双方责任约定的要素。结果美国食品药品管理局(U.S.Food and Drug Administration,FDA)建议委托双方签订质量协议,欧盟药品管理局(European Medicines Agency,EMA)要求双方签订委托合同,委托双方应在协议或合同中明确委托活动、双方责任、争议解决条款、协议内容变更程序及双方的沟通程序,其中最重要的两点是双方责任划分和协议内容变更程序。结论实施上市许可制度后,委托生产的委托方范围及受托范围均扩大,委托生产更易出现。委托协议中应特别明确产品的放行权、建立委托双方的沟通计划、明确协议内容的变更及验证程序和产品运输及储存条件。且监管部门有必要制定委托生产协议相关指南,指导委托双方约定责任义务,最终保证生产出的药品符合GMP和上市许可。展开更多
Objective To provide suggestions for helping marketing authorization holders(MAHs)to develop an effective and compliant pharmacovigilance system.Methods The construction strategies of pharmacovigilance system of the m...Objective To provide suggestions for helping marketing authorization holders(MAHs)to develop an effective and compliant pharmacovigilance system.Methods The construction strategies of pharmacovigilance system of the multinational pharmaceutical companies were analyzed based on the requirements of regulations and laws.Results and Conclusion There are some gaps between local and multinational pharmaceutical companies in the construction of pharmacovigilance system.We can learn from the experience of multinational pharmaceutical companies to improve the pharmacovigilance system,which includes building a sound pharmacovigilance organizational structure,establishing a series of operational system files and cultivating professional talents.MAHs of China should improve the structure of enterprise pharmacovigilance system.Besides,members of Drug Safety Committee should be department managers with higher position so that they can fulfil the responsibilities of risk assessment.If MAHs possess a large variety and quantity of products,a Drug Safety Committee should be established to ensure the timely discovery of risks.In addition,MAHs should pay attention to the implementation of related regulations and laws on pharmacovigilance and establish compliant,effective and operatable files combing with the actual operation of pharmacovigilance system.Finally,MAHs should introduce and train pharmacovigilance talents,and hire pharmacovigilance experts as consultants to solve the problem of talent shortage.展开更多
It is vital segment to choose the right comparator product during the development and study of generic medicinal product, and this is also definitely specified in the relevant documents from the China Food and Drug Ad...It is vital segment to choose the right comparator product during the development and study of generic medicinal product, and this is also definitely specified in the relevant documents from the China Food and Drug Administration (CFDA)that the comparator product should be innovator product or internationally recognized same medicinal product,which is used in the re-evaluation of generic medicinal product or marketed authorization application of the generic medicinal product.To facilitate the domestic and foreign pharmaceutical enterprises to choose and determine comparator product,four medicinal product evaluation procedures,as well as the corresponding marketed medicinal product list,are detailed elaborated in this paper.At the same time, by taking the Mifepristone Tablet (200mg)as example,the search and determination process of the comparator product for generic medicinal product application in the EU is illustrated with the combination of different marketed medicinal product lists.展开更多
文摘目的为药品上市许可制度下委托生产双方的责任约定提供建议。方法通过查阅国内外法规及文献,分析上市许可制度下,美欧对药品委托生产的要求及委托双方责任约定的要素。结果美国食品药品管理局(U.S.Food and Drug Administration,FDA)建议委托双方签订质量协议,欧盟药品管理局(European Medicines Agency,EMA)要求双方签订委托合同,委托双方应在协议或合同中明确委托活动、双方责任、争议解决条款、协议内容变更程序及双方的沟通程序,其中最重要的两点是双方责任划分和协议内容变更程序。结论实施上市许可制度后,委托生产的委托方范围及受托范围均扩大,委托生产更易出现。委托协议中应特别明确产品的放行权、建立委托双方的沟通计划、明确协议内容的变更及验证程序和产品运输及储存条件。且监管部门有必要制定委托生产协议相关指南,指导委托双方约定责任义务,最终保证生产出的药品符合GMP和上市许可。
基金Integration Application Status and Problems Investigation of ICH Q8,Q9,Q10 across the Product Life Cycle(No.20210605).
文摘Objective To provide suggestions for helping marketing authorization holders(MAHs)to develop an effective and compliant pharmacovigilance system.Methods The construction strategies of pharmacovigilance system of the multinational pharmaceutical companies were analyzed based on the requirements of regulations and laws.Results and Conclusion There are some gaps between local and multinational pharmaceutical companies in the construction of pharmacovigilance system.We can learn from the experience of multinational pharmaceutical companies to improve the pharmacovigilance system,which includes building a sound pharmacovigilance organizational structure,establishing a series of operational system files and cultivating professional talents.MAHs of China should improve the structure of enterprise pharmacovigilance system.Besides,members of Drug Safety Committee should be department managers with higher position so that they can fulfil the responsibilities of risk assessment.If MAHs possess a large variety and quantity of products,a Drug Safety Committee should be established to ensure the timely discovery of risks.In addition,MAHs should pay attention to the implementation of related regulations and laws on pharmacovigilance and establish compliant,effective and operatable files combing with the actual operation of pharmacovigilance system.Finally,MAHs should introduce and train pharmacovigilance talents,and hire pharmacovigilance experts as consultants to solve the problem of talent shortage.
基金National Science and Technology Major Projects for ‘Major New Drugs Innovation and Development’(Grant No.2017ZX09101001,Beijing,China)
文摘It is vital segment to choose the right comparator product during the development and study of generic medicinal product, and this is also definitely specified in the relevant documents from the China Food and Drug Administration (CFDA)that the comparator product should be innovator product or internationally recognized same medicinal product,which is used in the re-evaluation of generic medicinal product or marketed authorization application of the generic medicinal product.To facilitate the domestic and foreign pharmaceutical enterprises to choose and determine comparator product,four medicinal product evaluation procedures,as well as the corresponding marketed medicinal product list,are detailed elaborated in this paper.At the same time, by taking the Mifepristone Tablet (200mg)as example,the search and determination process of the comparator product for generic medicinal product application in the EU is illustrated with the combination of different marketed medicinal product lists.
